Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Sendal Therapeutics
Cambridge, Massachusetts, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Senda Biosciences is developing programmable medicines using natural nanoparticles and information molecules like mRNA for targeted delivery. Preclinical data in small and large animals across disease models supports tissue-specific programming, with plans to nominate first drug candidates and enter clinic in 2024.
- Therapeutic areas
- OncologyCardiovascularMetabolic Disorders
- Modalities
- NanoparticlemRNAsiRNAGene editor
- Industry
- Biotech
Beyond the preview
Go deeper on Sendal Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sendal Therapeutics.